Investor Relations Home

Corporate Profile

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally.

Title
Download Documentation NeuroDerm November 2016 Corporate Presentation

Recent News

More >>
DateTitle 
12/07/16NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares
REHOVOT, Israel, Dec. 07, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of a follow-on offering of 4,000,000 shares of its ordinary shares at a price to the public of $18.75 per share. All of the ordinary shares are being offered by NeuroDerm. In addition, NeuroDerm has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares at... 
Printer Friendly Version
12/06/16NeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares
REHOVOT, Israel, Dec. 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of a follow-on offering of its ordinary shares. All of the ordinary shares will be offered by NeuroDerm. The company expects to use the net proceeds of the offering to fund ongoing and planned clinical trials for its product candidates and the development of related devices and for researc... 
Printer Friendly Version
12/05/16NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development
- Company to pursue comparative bioavailability regulatory route instead of clinical efficacy development route - - NeuroDerm to add patients to its long-term safety trial - - Conference call and webcast today at 8:00 a.m. ET - REHOVOT, Israel, Dec. 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that following its End-of-Phase 2 meeting with the United States Food... 
Printer Friendly Version

Upcoming Events | Past Events

More >>
There are currently no events scheduled.